- Investing.com
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Metrics to compare | GLPGa | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGLPGaPeersSector | |
---|---|---|---|---|
P/E Ratio | −1,229.5x | −2.5x | −0.7x | |
PEG Ratio | 18.78 | −0.11 | 0.00 | |
Price/Book | 0.5x | 1.4x | 2.6x | |
Price / LTM Sales | 5.7x | 7.6x | 3.1x | |
Upside (Analyst Target) | - | 169.9% | 46.7% | |
Fair Value Upside | Unlock | 3.8% | 8.1% | Unlock |